Latest News on INBX

Financial News Based On Company


Advertisement
Advertisement

Form 8K Inhibrx Biosciences Inc For: 17 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-inhibrx-biosciences-inc-for-17-november-93CH-5711006
Investing.com reported on an 8K filing from Inhibrx Biosciences Inc (INBX) for November 17. The article briefly mentions the stock's performance and includes general market data.

Form 8K Inhibrx Biosciences Inc For: 17 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-inhibrx-biosciences-inc-for-17-november-93CH-4965274
This article announces that Inhibrx Biosciences Inc. filed a Form 8K on November 17, 2026. The filing is available through Investing.com and is related to the company's stock, INBX. No further details of the 8K content are provided.

Inhibrx Biosciences Analyst Cuts Price Target Despite Data Catalysts In 2027

https://www.benzinga.com/analyst-stock-ratings/price-target/26/11/63302664/inhibrx-biosciences-analyst-cuts-price-target-despite-data-catalysts-in-2027
Despite Inhibrx Biosciences (NASDAQ:INBX) reporting a wider-than-expected net loss for Q3 2026, primarily due to higher other expenses, HC Wainwright analyst Robert Burns maintained a Buy rating while lowering the price target from $245 to $220. The company's cash reserves are expected to provide an operational runway into Q2 2028, supporting several key data catalysts anticipated in 2027, including potential FDA approval for ozekibart and initial readouts from trials for ordastobart.

HC Wainwright & Co. maintains Inhibrx Biosciences at Buy, lowers price target to $220 from $245

https://www.tradingview.com/news/tradingview:80e33198e8cdb:0-hc-wainwright-co-maintains-inhibrx-biosciences-at-buy-lowers-price-target-to-220-from-245/
HC Wainwright & Co. has reiterated a Buy rating for Inhibrx Biosciences (INBX) but reduced its price target from $245 to $220, a 10.2% decrease. This new price target suggests a potential upside of 164.1% from the stock's closing price of $83.30 on November 13. Investors can find more details on price target data and analyst recommendations on TradingView's Forecasts tab and News Flow.

Pfizer license brings Inhibrx Biosciences (INBX) $2M as its quarterly loss widens.

https://www.stocktitan.net/sec-filings/INBX/10-q-inhibrx-biosciences-inc-quarterly-earnings-report-af89227bcac4.html
Inhibrx Biosciences (INBX) reported a Q3 2026 net loss of $38.7 million, up 10% from the previous year, despite generating $2.0 million in revenue from an upfront payment under its Pfizer license. The company's cash reserves stood at $199.469 million with long-term debt at $276.701 million, but it believes existing cash will fund operations for at least 12 months. Inhibrx also provided updates on its clinical pipeline, including positive Phase 2 HexAgon results for ordastobart and the FDA's acceptance of ozekibart's chondrosarcoma BLA for filing.
Advertisement

Form S-3ASR Inhibrx Biosciences Inc For: 14 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-s3asr-inhibrx-biosciences-inc-for-14-november-93CH-4982513
This article announces the filing of Form S-3ASR by Inhibrx Biosciences Inc. on November 14, 2026. The brief notice from Investing.com provides no further details about the content or implications of the filing. It is a standard regulatory update for investors interested in the company (INBX).

Inhibrx had $199.5 million in cash Sept. 30; two cancer trial results are expected around mid-2027.

https://www.stocktitan.net/news/INBX/inhibrx-reports-third-quarter-2026-financial-1qrjurhf1cyv.html
Inhibrx Biosciences (INBX) reported a third-quarter 2026 net loss of $38.7 million, widening from $35.3 million a year earlier, despite increased revenue from a Pfizer patent license. The company's cash and equivalents grew to $199.5 million as of September 30, 2026. Looking ahead, Inhibrx expects initial Phase 2 expansion results for its ordastobart program in HPV-positive oropharyngeal cancer and initial Phase 1/2 results for ordastobart in non-small cell lung cancer around mid-2027.

Form 8K Inhibrx Biosciences Inc For: 13 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-inhibrx-biosciences-inc-for-13-november-93CH-5703977
This article announces that Inhibrx Biosciences Inc. filed a Form 8K for November 13. It includes a brief mention of the company's stock symbol (INBX) and its performance, showing a -5.07% change. The article primarily serves as a notice about the filing, with a large portion of the page dedicated to market data, trending stocks, and various investment tools provided by Investing.com.

With two oncology candidates, Inhibrx Biosciences (INBX) may sell shares to fund research.

https://www.stocktitan.net/sec-filings/INBX/s-3asr-inhibrx-biosciences-inc-sec-filing-a2e9f7cfa787.html
Inhibrx Biosciences (INBX) has filed a sales-agreement prospectus to offer up to $150 million in common stock through an at-the-market program to fund general corporate purposes, including research and development for its two oncology candidates, ozekibart (INBRX-109) and ordastobart (INBRX-106). The company, a clinical-stage biopharmaceutical firm, is advancing these candidates in various cancer types, with ozekibart's biologics license application for chondrosarcoma accepted by the FDA in June 2026. This offering highlights the company's strategy to secure capital for its ongoing clinical programs and potential acquisitions.

Inhibrx Biosciences, Inc. (INBX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/INBX/
This article provides a comprehensive overview of Inhibrx Biosciences, Inc. (INBX), including its current stock price, recent performance metrics, and key financial data. It details the company's profile as a clinical-stage biopharmaceutical company, its therapeutic candidates, and analyst insights, along with comparisons to the S&P 500 benchmark.
Advertisement

One holder reports sole voting power over 952,959 Inhibrx Biosciences (INBX) shares.

https://www.stocktitan.net/sec-filings/INBX/schedule-13g-a-inhibrx-biosciences-inc-amended-passive-investment-dis-22e2f93e36a5.html
Schonfeld Strategic Advisors LLC has reported beneficial ownership of 952,959 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 6.47% of the class. The firm stated it holds sole voting and dispositive power over these shares, with clients being the record owners who retain rights to dividends and sale proceeds. This disclosure was made in an amended passive investment filing (SCHEDULE 13G/A) with the SEC.

Inhibrx Biosciences, Inc. (INBX) Reports Q3 2026 Results

https://www.tradingview.com/news/tradingview:d389856a0631e:0-inhibrx-biosciences-inc-inbx-reports-q3-2026-results/
Inhibrx Biosciences, Inc. (INBX) has reported its third-quarter 2026 financial results. However, the provided release did not include any specific financial figures or comparisons, making it impossible to assess performance. The company is a clinical-stage biopharmaceutical firm with two ongoing clinical programs, and further financial details and clinical milestones are needed for a comprehensive evaluation.

Form 8K Inhibrx Biosciences Inc For: 13 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-inhibrx-biosciences-inc-for-13-november-93CH-4981903
This article announces that Inhibrx Biosciences Inc. filed a Form 8K on November 13, 2026. The filing is an important regulatory disclosure for the company, and the brief notice provides the date of the filing. It also lists the stock symbol INBX, showing a -5.07% change.

Form 8K Inhibrx Biosciences Inc For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-inhibrx-biosciences-inc-for-13-november-93CH-4957797
Investing.com reports that Inhibrx Biosciences Inc. filed a Form 8K on November 13. The article is a brief notification of this filing, also noting a -5.07% change in the company's stock, INBX. No further details about the content of the 8K filing are provided.

How Inhibrx Biosciences Inc Com (INBX) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/52/How_Inhibrx_Biosciences_Inc_Com_INBX_Affects_Rotational_Strategy_Timing_110526102801_1793935681.html
This article analyzes Inhibrx Biosciences Inc Com (INBX) through AI-generated trading strategies for different risk profiles and holding periods. It identifies a positive near-term sentiment with a weak mid-term bias within a long-term strength context. Key findings include an exceptional risk-reward setup targeting a 28.0% gain versus 0.3% risk, and provides specific entry, target, and stop levels for position trading, momentum breakout, and risk hedging strategies.
Advertisement

Inhibrx Biosciences stock faces a busy clinical-data calendar

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inhibrx-biosciences-stock-faces-a-busy-clinical-data-calendar/70460463
Inhibrx Biosciences (INBX) is set to present new analyses of ozekibart (INBRX-109) at the Connective Tissue Oncology Society (CTOS) meeting in November, focusing on progression-free survival and subgroup findings in conventional chondrosarcoma, as well as its use in Ewing sarcoma. The clinical-stage biopharmaceutical company's pipeline and development progress will be highlighted through these presentations, providing investors with key updates on its biologic therapeutic candidates. The company's focus is on clinical development, with its progress tied to trial results and scientific disclosures.

Form 4 Inhibrx Biosciences Inc: Douglas Forsyth (Director) For: 3 June

https://uk.investing.com/news/stock-market-news/form-4-inhibrx-biosciences-inc-douglas-forsyth-director-for-3-june-93CH-4947966
This article reports on a Form 4 filing for Inhibrx Biosciences Inc, indicating that Douglas Forsyth, a Director, made a transaction on June 3rd. Form 4 filings are required by the SEC to disclose changes in beneficial ownership of a company's securities by its directors, officers, and principal stockholders. The article is a brief announcement of this regulatory disclosure.

Form 4 Inhibrx Biosciences Inc: Kimberly Manhard (Director) For: 3 June By Investing.com

https://in.investing.com/news/stock-market-news/form-4-inhibrx-biosciences-inc-kimberly-manhard-director-for-3-june-93CH-5670394
This article reports on a Form 4 filing for Inhibrx Biosciences Inc., detailing an insider transaction by Kimberly Manhard, a Director, on June 3rd. Form 4 filings are used to declare changes in beneficial ownership of securities by a company's officers, directors, and principal stockholders. The article itself is very brief, primarily serving as an announcement of the filing.

Inhibrx Biosciences, Inc. (INBX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/INBX/seasonality/
This article displays the seasonal returns chart for Inhibrx Biosciences, Inc. (INBX), showing average monthly price returns from 2024 to 2026. The information is presented in a Yahoo Finance context, including current stock price and market status.

Bank of America Reveals 2.4% Ownership Stake in Inhibrx Biosciences

https://kalkinemedia.com/us/news/announcements/bank-of-america-reveals-24-ownership-stake-in-inhibrx-biosciences
Bank of America Corp /DE/ has disclosed an amended Schedule 13G, reporting a beneficial ownership of 357,318 shares in Inhibrx Biosciences, Inc. as of September 30, 2026. This stake represents 2.4% of Inhibrx Biosciences' total outstanding shares and is held through various wholly-owned subsidiaries with shared voting and dispositive powers. The filing details the breakdown of shared authority among its subsidiaries like BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.
Advertisement

Inhibrx Biosciences Down Over 26%, On Track for Record Percent Decrease -- Data Talk

https://www.moomoo.com/news/post/1002692285/inhibrx-biosciences-down-over-26-on-track-for-record-percent
Inhibrx Biosciences (INBX) stock experienced a significant decline of over 26% on Thursday, heading towards its largest percentage decrease since its IPO. The biotech company's stock has been performing poorly, down 65.3% year-to-date and trading at a record low of $14.28.

Bank of America amends its passive stake disclosure for Inhibrx Biosciences (INBX).

https://www.stocktitan.net/sec-filings/INBX/schedule-13g-a-inhibrx-biosciences-inc-amended-passive-investment-dis-ef41e64f39fd.html
Bank of America Corporation and its wholly owned subsidiaries have filed an amended Schedule 13G/A, disclosing a 2.4% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX). This represents ownership of 357,318 shares, with shared voting power over 357,306 shares and shared dispositive power over 357,318 shares, based on 14,717,660 shares outstanding as of August 7, 2026. The filing indicates a passive investment, not intended to influence control of the issuer.

Avoiding Lag: Real-Time Signals in (INBX) Movement

https://news.stocktradersdaily.com/news_release/150/Avoiding_Lag:_Real-Time_Signals_in_INBX_Movement_102626103802_1793068682.html
This article provides an analysis of Inhibrx Biosciences Inc Com (NASDAQ: INBX) with a neutral near and mid-term outlook, but a positive long-term bias. It highlights a mid-channel oscillation pattern and an exceptional 84.6:1 risk-reward setup, targeting a 24.4% gain against a 0.3% risk. The report also details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various horizons.

Inhibrx Biosciences, Inc. (INBX) stock price, news, quote and history

https://au.finance.yahoo.com/quote/INBX/
This article provides a detailed overview of Inhibrx Biosciences, Inc. (INBX), including its current stock price, historical performance, and key financial metrics. It highlights the company's clinical-stage biopharmaceutical operations, therapeutic candidates, and analyst ratings. The report also includes performance comparisons against the S&P 500 and earnings trends.

Inhibrx Biosciences, Inc. (INBX) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/INBX/
This article provides a detailed overview of Inhibrx Biosciences, Inc. (INBX) stock, including its current price, historical performance, and key financial metrics. It highlights the company's clinical-stage biopharmaceutical focus and its therapeutic candidates, INBRX-109 and INBRX-106. The report also includes analyst ratings and a comparison of INBX's returns against the S&P 500.
Advertisement

Inhibrx Biosciences, Inc. Estimates – NASDAQ:INBX

https://www.tradingview.com/symbols/NASDAQ-INBX/financials-estimates/
This page from TradingView provides financial data and analyst estimates for Inhibrx Biosciences, Inc. (NASDAQ: INBX). It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

(INBX) Volatility Zones as Tactical Triggers

https://news.stocktradersdaily.com/news_release/90/INBX_Volatility_Zones_as_Tactical_Triggers_101626075601_1792194961.html
This analysis for Inhibrx Biosciences Inc Com (NASDAQ: INBX) identifies volatility zones as tactical triggers, noting weak near and mid-term sentiment but a strong long-term outlook. It details proprietary signals, institutional trading strategies (Position, Momentum Breakout, Risk Hedging), and a multi-timeframe signal analysis, highlighting an exceptional risk-reward setup.

CEO Mark Lappe buys 10,040 shares in Inhibrx Biosciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/ceo-mark-lappe-buys-10-040-shares-in-inhibrx-biosciences-stock/70334798
Inhibrx Biosciences CEO Mark Lappe purchased 10,040 shares of the company's stock on October 14, 2026, through two family trusts. This insider buying follows a significant 145% return for the stock over the past year and precedes several upcoming presentations on the company's cancer programs. Inhibrx Biosciences (INBX) will present updated clinical data at four conferences, highlighting promising results for its cancer treatments.

Form 4 Inhibrx Biosciences Inc: Mark Lappe (Director, CEO) For: 14 October

https://in.investing.com/news/stock-market-news/form-4-inhibrx-biosciences-inc-mark-lappe-director-ceo-for-14-october-93CH-5633929
This article reports a Form 4 filing for Inhibrx Biosciences Inc, detailing a transaction by Mark Lappe, who serves as both Director and CEO. The filing pertains to an event on October 14. The piece briefly mentions the company's stock symbol INBX and its recent performance.

Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported.

https://www.stocktitan.net/sec-filings/INBX/form-4-inhibrx-biosciences-inc-insider-trading-activity-62760d0c322c.html
The CEO of Inhibrx Biosciences, Mark Lappe, reported that two family trusts, the Lappe Family Trust and the Lappe Descendants’ Trust, purchased a combined 10,040 shares of common stock on October 14, 2026. These purchases were made across several transactions at weighted-average prices ranging from $84.0707 to $85.7600 per share. Additionally, a separate Roth IRA holding for Mark Lappe shows 54,865 shares, and no Rule 10b5-1 trading plan was reported.
Advertisement

Inhibrx CEO Mark Lappe buys over $848k in company stock

https://www.investing.com/news/insider-trading-news/inhibrx-ceo-mark-lappe-buys-over-848k-in-company-stock-93CH-4950248
Inhibrx CEO Mark Lappe recently purchased over $848,000 worth of company stock through various trusts, acquiring 10,040 shares at prices ranging from $84.0707 to $85.76 per share. This comes as the stock shows a 145% return over the past year, although InvestingPro suggests it is overvalued. The company also announced positive Phase 2 trial results for its drug INBRX-106, with analysts offering varied perspectives on its future performance.

Form 4 Inhibrx Biosciences Inc: Mark Lappe (Director, CEO) For: 14 October

https://uk.investing.com/news/stock-market-news/form-4-inhibrx-biosciences-inc-mark-lappe-director-ceo-for-14-october-93CH-4911016
This article reports a Form 4 filing for Inhibrx Biosciences Inc, indicating that Mark Lappe, who serves as a Director and CEO, had a transaction on October 14. The filing provides details about insider trading activity for the company.

Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?

https://ca.finance.yahoo.com/news/inhibrx-biosciences-inbx-global-data-141445384.html
Inhibrx Biosciences (INBX) is presenting updated data for its clinical-stage candidates INBRX-106 and INBRX-109 at major oncology conferences, aiming to bring its clinical data to wider scrutiny. This move is crucial for validating previous mid-stage data and the ozekibart program, especially given the company's high-risk, clinical-stage investment narrative, significant reliance on external financing, and a recent stock pullback. Investors are assessing whether these presentations can solidify the company's pipeline credibility and address concerns about its financial health and valuation.

Cancer-study presentations from Inhibrx will take place in Madrid, Miami and Seoul.

https://www.stocktitan.net/news/INBX/inhibrx-announces-participation-in-upcoming-scientific-c4zn6d512hj9.html
Inhibrx Biosciences (INBX) announced it will present studies on ordastobart and ozekibart at three upcoming scientific conferences in October and November 2026. These presentations will cover various cancer treatments, including head and neck cancer, conventional chondrosarcoma, and Ewing sarcoma, detailing phase 2 study results and subgroup analyses. The company will provide access to these presentations on its investor relations website.

Inhibrx Announces Participation in Upcoming Scientific Conferences

https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conferences-302907553.html
Inhibrx Biosciences, Inc. announced its participation in several upcoming scientific conferences in October and November 2026. The company will present data on its biologic therapeutic candidates, ordastobart (INBRX-106) and ozekibart (INBRX-109), for various cancer treatments including head and neck squamous cell carcinoma, chondrosarcoma, and Ewing sarcoma. Presentations will be held at the ESMO Congress, MSTS Annual Meeting, and CTOS Annual Meeting.
Advertisement

Inhibrx Biosciences stock falls 1.62 percent on October 5

https://www.ad-hoc-news.de/boerse/news/corporate-news/inhibrx-biosciences-stock-falls-1-62-percent-on-october-5/70234279
Inhibrx Biosciences stock fell 1.62 percent to USD 95.42 on October 5, 2026, after its Q2 2026 diluted loss of USD 2.34 per share missed the consensus estimate. The company continues to focus on its clinical pipeline, but high cash burn and the binary nature of biotechnology investments remain key valuation factors. Analysts maintain an average target price of USD 197.50, significantly higher than the current trading price.

Inhibrx updates pipeline data as analysts rate Inhibrx stock Moderate Buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inhibrx-updates-pipeline-data-as-analysts-rate-inhibrx-stock-moderate-buy/70232779
Inhibrx Biosciences updated its corporate presentation, highlighting pipeline progress, while analysts issued a "Moderate Buy" consensus despite varied valuation expectations. The company reported a Q2 2026 loss of USD 2.34 per share, missing estimates. Analysts have an average 12-month price target of USD 197.50, significantly above its current Nasdaq trading price, emphasizing the importance of clinical milestones over revenue.

Inhibrx Biosciences stock gets a Moderate Buy consensus at USD 197.50

https://www.ad-hoc-news.de/boerse/news/corporate-news/inhibrx-biosciences-stock-gets-a-moderate-buy-consensus-at-usd-197-50/70224735
Inhibrx Biosciences (INBX) has received a "Moderate Buy" consensus from six brokerages, with an average 12-month price target of USD 197.50, significantly higher than its current price of USD 96.99. This optimism stems from positive Phase 2 trial data for INBRX-106, which showed a 48.3 percent objective response rate. Despite missing Q2 2026 earnings estimates, the clinical results offer a clear catalyst for the stock, though financial performance remains a key factor.

Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

https://www.marketbeat.com/articles/inhibrxs-insider-buying-adds-fuel-to-a-high-short-interest-biotech-setup/
Inhibrx Biosciences' CEO, Mark Lappe, invested over $3.6 million in company shares after a 17% stock drop, despite strong Phase 2 clinical data for INBRX-106 which showed a 48.3% objective response rate in head and neck cancer. This insider buying, combined with a 28% short interest in the stock and pending FDA action on ozekibart, suggests a high potential for a short squeeze and a valuation reset. The company also has a near-term catalyst with a potential FDA approval for ozekibart, which would provide a new revenue stream as the first systemic treatment for conventional chondrosarcoma.

Inhibrx Biosciences Insider Bought Shares Worth $998,784, According to a Recent SEC Filing

https://finance.yahoo.com/markets/stocks/articles/inhibrx-biosciences-insider-bought-shares-215241951.html
Inhibrx Biosciences Director and CEO, Mark Lappe, purchased 10,000 shares of the company's stock on September 25, 2026. This transaction is valued at $998,784. The information was disclosed in a recent SEC filing.
Advertisement

Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-inhibrx-biosciences-inc-for-28-september-93CH-2712934
The article reports on a Form 4 filing for Inhibrx Biosciences Inc. for September 28, 2026. It notes that the company's stock symbol is INBX, which saw a 3.65% increase. The content is brief, primarily serving as an announcement of the filing.

Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock

https://ng.investing.com/news/stock-market-news/inhibrx-biosciences-ceo-mark-lappe-buys-998k-in-company-stock-93CH-2712931
Inhibrx Biosciences CEO Mark Lappe recently purchased nearly $1 million worth of company stock across multiple transactions on September 25 and 28, 2026. These purchases occurred despite the stock being down 9% over the past week, though it has seen a 211% return over the past year. Analysts maintain price targets between $230 and $325, and the company recently reported positive Phase 2 trial results for its drug INBRX-106 in head and neck cancer.

Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock

https://www.investing.com/news/insider-trading-news/inhibrx-biosciences-ceo-mark-lappe-buys-998k-in-company-stock-93CH-4921342
Inhibrx Biosciences CEO Mark Lappe recently purchased nearly $1 million worth of company stock, acquiring shares on September 25 and 28, 2026, at prices ranging from $98.8659 to $101.702 per share. These transactions, made through the Lappe Family Trust, occurred despite the stock's recent 9% dip, though it has seen a 211% return over the past year. Analysts have price targets between $230 and $325, and the company recently reported positive Phase 2 trial results for its cancer drug INBRX-106.

Inhibrx Biosciences posts updated corporate presentation highlighting INBRX-106 and ozekibart clinical progress

https://www.tradingview.com/news/tradingview:6172c9edb3559:0-inhibrx-biosciences-posts-updated-corporate-presentation-highlighting-inbrx-106-and-ozekibart-clinical-progress/
Inhibrx Biosciences has released an updated investor presentation detailing positive clinical results for its drugs INBRX-106 and ozekibart. INBRX-106 showed strong interim Phase 2 data with improved durability and a planned Phase 2 expansion for potential accelerated approval, while ozekibart met its primary endpoint in a registrational trial for chondrosarcoma. The company furnished the presentation as an Exhibit 99.1 on its investor website on September 28, 2026.

Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares.

https://www.stocktitan.net/sec-filings/INBX/form-4-inhibrx-biosciences-inc-insider-trading-activity-fe0dd7c8cc10.html
Inhibrx Biosciences CEO Mark P. Lappe's family trust purchased 10,000 common shares of INBX over two days, September 25 and 28, 2026. The shares were acquired in four separate transactions at weighted-average prices ranging from $98.8659 to $101.7020. This insider transaction was reported via a Form 4 filing, with no Rule 10b5-1 plan indicated, and reflects a positive sentiment for the company.
Advertisement

Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com

https://in.investing.com/news/stock-market-news/form-4-inhibrx-biosciences-inc-for-28-september-93CH-5609864
This article from Investing.com reports the filing of a Form 4 by Inhibrx Biosciences Inc. for activity on September 28. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be submitted by company insiders, such as officers, directors, or beneficial owners, whenever they trade stock in their own company. It indicates transactions in company stock by insiders of Inhibrx Biosciences Inc.

A bone cancer drug met its trial goal for Inhibrx Biosciences (INBX), delaying progression versus placebo.

https://www.stocktitan.net/sec-filings/INBX/8-k-inhibrx-biosciences-inc-reports-material-event-6c80a322bb99.html
Inhibrx Biosciences (INBX) announced positive clinical trial results for its drug ozekibart, which met its primary endpoint in a chondrosarcoma registrational trial by significantly prolonging median progression-free survival (PFS) to 5.52 months compared to 2.66 months for placebo. The company also presented promising data for INBRX-106 in head and neck squamous cell carcinoma, showing superior objective response rates and PFS when combined with pembrolizumab. These developments highlight potential accelerated approval pathways and significant market opportunities for both drug candidates.

Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock

https://www.investing.com/news/insider-trading-news/inhibrx-biosciences-director-jon-kayyem-buys-500000-in-common-stock-93CH-4914072
Jon Faiz Kayyem, a director at Inhibrx Biosciences, Inc. (NASDAQ:INBX), recently purchased 5,000 shares of common stock for $100.00 per share, totaling $500,000. This transaction occurred on September 23, 2026, with the stock trading near $100 after a significant 247% gain over the past year. The purchase details reveal Kayyem's indirect beneficial ownership across several trusts and custodial accounts, while recent positive Phase 2 trial results and maintained "Buy" ratings from analysts like H.C. Wainwright and Stifel indicate ongoing interest in Inhibrx's potential.

Inhibrx Biosciences stock gains on insider buying and trial progress

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inhibrx-biosciences-stock-gains-on-insider-buying-and-trial-progress/70148138
Inhibrx Biosciences stock is gaining attention due to significant insider buying, with executives committing approximately USD 4.0 million to share purchases through September 16, 2026. This activity coincides with the company reporting encouraging Phase 2 data for its INBRX-106 antibody in head and neck cancer, showing an interim median progression-free survival of 9.6 months. The combination of insider confidence and positive clinical results provides a strong signal for investors.

Inhibrx Biosciences stock gains institutional support as Bank of America invests

https://www.ad-hoc-news.de/boerse/news/nebenwerte/inhibrx-biosciences-stock-gains-institutional-support-as-bank-of-america/70138375
Inhibrx Biosciences (INBX) stock has seen increased institutional investment, with Bank of America Corp DE disclosing a new $79.70 million stake and Tidal Investments LLC purchasing 10,170 shares. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $197.50, suggesting significant upside despite the risks inherent in clinical-stage biotechnology. The stock was trading at $109.35 on Nasdaq as of September 19, 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement